Guided Therapeutics (GTHP) Raw Materials (2014 - 2021)

Guided Therapeutics has disclosed Raw Materials across 8 years of filings, most recently posting $1.3 million for Q1 2021.

• Raw Materials for Q1 2021 came in at $1.3 million, up 63.09% year-over-year; the trailing twelve-month figure through Mar 2021 was $1.3 million (up 63.09% YoY), and the FY2020 annual result was $1.3 million, up 63.38% from the prior year.
• Raw Materials came in at $1.3 million for Q1 2021 at Guided Therapeutics, roughly flat from $1.3 million in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $1.3 million in Q1 2021 to a low of $781000.0 in Q1 2019.
• The 5-year median for Raw Materials is $789000.0 (2017), against an average of $844294.1.
• Across the five-year window, Raw Materials retreated 7.77% in 2017 and soared 63.38% in 2020, its largest moves.
• Guided Therapeutics' Raw Materials stood at $789000.0 in 2017, then retreated by 0.76% to $783000.0 in 2018, then slipped by 0.26% to $781000.0 in 2019, then jumped by 63.38% to $1.3 million in 2020, then climbed by 0.08% to $1.3 million in 2021.
• The last three Raw Materials figures came in at $1.3 million (Q1 2021), $1.3 million (Q4 2020), and $782000.0 (Q3 2020), per Business Quant data.